Victory Capital Management Inc. Has $616,000 Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Victory Capital Management Inc. lowered its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 2.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 389,886 shares of the biopharmaceutical company’s stock after selling 8,980 shares during the period. Victory Capital Management Inc.’s holdings in Regulus Therapeutics were worth $616,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of RGLS. Jane Street Group LLC bought a new position in Regulus Therapeutics in the third quarter valued at about $46,000. JPMorgan Chase & Co. boosted its holdings in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Barclays PLC boosted its holdings in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Regulus Therapeutics in the third quarter valued at approximately $204,000. Finally, Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics in the third quarter valued at approximately $1,403,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Trading Up 0.7 %

Shares of RGLS opened at $1.37 on Friday. The company has a market cap of $90.75 million, a PE ratio of -1.28 and a beta of 1.42. The stock has a 50-day moving average price of $1.27 and a 200-day moving average price of $1.45. Regulus Therapeutics Inc. has a 12-month low of $0.83 and a 12-month high of $3.00.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same period in the prior year, the company posted ($0.40) earnings per share. As a group, analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $28.00 price target on shares of Regulus Therapeutics in a research note on Monday, March 17th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday, March 14th.

Insider Buying and Selling

In other Regulus Therapeutics news, VP Christopher Ray Aker sold 38,547 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares of the company’s stock, valued at $68,838.84. The trade was a 41.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph P. Hagan purchased 50,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was bought at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the purchase, the chief executive officer now directly owns 260,808 shares in the company, valued at approximately $284,280.72. This trade represents a 23.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 223,998 shares of company stock worth $282,237 in the last quarter. 4.35% of the stock is owned by insiders.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.